Trastuzumab in the treatment of breast cancer

被引：221

作者：

Hortobagyi, GN ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 16期

关键词：

D O I：

10.1056/NEJMe058196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1734 / 1736

页数：3

共 11 条

[1] DIFFERENTIAL RESPONSES OF HUMAN TUMOR-CELL LINES TO ANTI-P185(HER2) MONOCLONAL-ANTIBODIES [J].

LEWIS, GD ;

FIGARI, I ;

FENDLY, B ;

WONG, WL ;

CARTER, P ;

GORMAN, C ;

SHEPARD, HM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 37 (04) :255-263

[2] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].

Marty, M ;

Cognetti, F ;

Maraninchi, D ;

Snyder, R ;

Mauriac, L ;

Tubiana-Hulin, M ;

Chan, S ;

Grimes, D ;

Antón, A ;

Lluch, A ;

Kennedy, J ;

O'Byrne, K ;

Conte, P ;

Green, M ;

Ward, C ;

Mayne, K ;

Extra, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274

[3] Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers [J].

Pegram, M ;

Hsu, S ;

Lewis, G ;

Pietras, R ;

Beryt, M ;

Sliwkowski, M ;

Coombs, D ;

Baly, D ;

Kabbinavar, F ;

Slamon, D .

ONCOGENE, 1999, 18 (13) :2241-2251

[4] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[5] Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs [J].

Pietras, RJ ;

Pegram, MD ;

Finn, RS ;

Maneval, DA ;

Slamon, DJ .

ONCOGENE, 1998, 17 (17) :2235-2249

[6]

Robert N, 2002, BREAST CANCER RES TR, V76, pS37

[7] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[8]

Sato J D, 1983, Mol Biol Med, V1, P511

[9] THE NEU GENE - AN ERBB-HOMOLOGOUS GENE DISTINCT FROM AND UNLINKED TO THE GENE ENCODING THE EGF RECEPTOR [J].

SCHECHTER, AL ;

HUNG, MC ;

VAIDYANATHAN, L ;

WEINBERG, RA ;

YANGFENG, TL ;

FRANCKE, U ;

ULLRICH, A ;

COUSSENS, L .

SCIENCE, 1985, 229 (4717) :976-978

[10] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

← 1 2 →